Rexulti (brexpiprazole) is a brand-name drug prescribed for certain mental health conditions. Rexulti comes as an oral tablet that’s typically taken once per day. The dosage can vary depending on what ...

With an FDA advisory committee recommendation in hand, Lundbeck and Otsuka’s Rexulti is one step closer to locking down a new indication in Alzheimer’s disease related agitation. In a 9-1 vote on ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the Joint Meeting of the ...

May 11 (UPI) --The Food and Drug Administration on Thursday announced the supplemental approval of Alzheimer's disease drug Rexulti, which treats agitation. Rexulti is an oral tablet that treats ...

Otsuka and Lundbeck’s CNS drug Rexulti has for the second time this year claimed the top spot as the leading TV drug ad spender. That’s according to the latest data out by real-time ad trackers ...

(RTTNews) - The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast ...

Alembic has received permission from the Food and Drug Administration for brexpiprazole tablets, which is the generic of Otsuka’s Rexulti. Brexpiprazole is an atypical antipsychotic used as an ...

Agitation is one of the most common symptoms of Alzheimer’s disease, leading patients to become restless or even verbally and physically aggressive. The FDA has approved the first drug to treat these ...

The Food and Drug Administration has given Otsuka and Lundbeck approval for Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer's disease.